Le Lézard

PADCEVtm Plus KEYTRUDAtm, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as ...

Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript

Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript

Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDTCompany ParticipantsXi-Yong Fu ...

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then ...

Manganese's resilience is key to its use as a catalyst in the oxygen evolution reaction

Scientists have long noted with interest that in one of nature's crucial chemical reactions—the oxygen evolution reaction—it ...